（原标题：重回4000！超级赛道攻势延续） 2026年第一个交易日，A股马上迎来了开门红。沪指拉升涨超1%，时隔34个交易日，盘中重回4000点；创业板指涨超2%，科技股、金融、周期板 块纷纷上涨。 随着"新质生产力"从政策概念走向产业落地，商业航天已不再是遥不可及的题材炒作，而是正在成长为大国博弈与经济转型的硬核引擎。 2025年见证了国防军工板块的强势复苏，尤其是涵盖卫星互联网的商业航天细分赛道，在年末更是呈现出加速上攻的态势。 元旦回来赛道延续攻势，卫星产业ETF(159218)跟踪的标的指数大涨3.78%，盘中资金抢筹积极，净流入量直接创下单日新高。 这种超额收益的背后，是资金对中国航天从"试验探索"迈向"工业化量产"这一历史性跨越的敏锐捕捉。 01 2026，开门红 板块题材上，脑机接口、保险、半导体、商业航天、创新药、游戏、有色金属板块涨幅居前；海南自贸区、旅游及酒店、银行、跨境支付、猪肉 板块跌幅居前。 具体来看，脑机接口板块早盘掀起涨停潮，倍益康30cm涨停，三博脑科、美好医疗、翔宇医疗等超20股涨停。 据报道，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑 ...

真没想到，脑机接口概念股又爆了！ 今年第一个交易日，脑机接口板块再次爆发，板块内51家成分股中有29家涨停，涨幅超过10%达到了惊人的40家。 1月5日，河南上市公司翔宇医疗（证券代码：688626.SH）收获今年首个20CM涨停，报收于72.6元/股，创下四年半来的新高。事实上，在经历近4个月的 回调后，自去年12月12日以来，翔宇医疗已经重拾涨势，15个交易日累计涨幅达到53%。 在此期间，公司获得接连不断的机构调研，12月22日—29日，公司陆续发布2则公告，近10天时间里接待了71家机构。 股价15天涨了53% 自去年以来，翔宇医疗的股价表现可谓抢眼。截至今年1月5日，翔宇医疗股价已经累计上涨了149.06%。 1月5日，翔宇医疗时隔半年再次收获"20CM"涨停，股价创下四年半来的新高。 翔宇医疗于2021年3月31日登陆A股上市，上市初始出现一波大涨，在当年6月28日盘中创出120.13元的历史最高点。 回顾翔宇医疗上市以来的走势可以看到，他们在2021年6月下旬创出120.13元历史最高点，之后就开始走出了长达3年的下跌行情，一直到2024年9月，翔 宇医疗整体趋势就是震荡走低，但是中间波动还是比 ...

今日（1月5日），亚太主要股指全线大涨，日经225指数收盘上涨2.97%报51832.8点，韩国综合指数上 涨3.43%报4457.52点，续创历史新高。 A股市场迎来"开门红"，主要股指放量大涨，沪指12连阳，涨超1%重返4000点上方；科创50指数大涨超 4%。 具体来看，两市股指高开高走，创业板指涨近3%，科创50指数大涨超4%。截至收盘，沪指涨1.38%报 4023.42点，深证成指涨2.24%，创业板指涨2.85%，科创50指数涨4.4%，沪深北三市合计成交25674亿 元。 全A近4200股飘红，保险板块强势，新华保险大涨近9%，中国太保涨超7%，双双创出新高；人脑工程 概念爆发，倍益康、三博脑科、翔宇医疗、伟思医疗等逾10股涨停；创新药概念强势，乐普医疗、冠昊 生物等涨停，百济神州涨超10%；存储芯片概念活跃，恒烁股份、普冉股份等涨停；AI应用概念崛起， 当虹科技、蓝色光标等涨停。此外，锋龙股份连续7日涨停，雷科防务、南兴股份分别收获4连板和3连 板。 值得注意的是，今日A股市场近20股成交额超过100亿元，其中中国卫星、三花智控分别成交194.5亿 元、192.1亿元，分别位居成交额第一和第二 ...

Group 1: Brain-Computer Interface - Neuralink, founded by Elon Musk, plans to start large-scale production of brain-computer interface devices in 2026 [5] - The brain-computer interface industry is expected to accelerate commercialization, with companies like Xiangyu Medical and Mylande experiencing significant stock price increases [9][10] - Analysts predict that the market size of the brain-computer interface industry will exceed $10 billion by 2030 [10] Group 2: Commercial Aerospace - Blue Arrow Aerospace has received approval for its IPO on the Sci-Tech Innovation Board, aiming to become the first publicly listed commercial rocket company in China [14] Group 3: Robotics - Morgan Stanley forecasts that China will ship 14,000 humanoid robots this year, with annual growth expected to double in the coming years, potentially exceeding 1 million units by 2034 [25] - The first full-body force-controlled humanoid robot, Q1, is set to be released, indicating a rapid acceleration in product iteration and market application [25] Group 4: AI Applications - Meta has announced the acquisition of AI agent company Manus to enhance its AI innovation efforts, with the integration of Manus into Meta's core consumer products [27] - The demand for AI applications is rapidly expanding, as indicated by the significant increase in token consumption, reflecting a shift from concept validation to revenue generation [30] - Tax Friend Co., mentioned in relation to AI applications, saw its stock price rise significantly following the announcement of expected AI application growth in early 2026 [30][31]

Group 1 - The medical device sector experienced a significant increase of 5.5% on January 5, with JinHao Medical leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] - Notable individual stock performances included JinHao Medical with a closing price of 38.23, up 20.03%, and BoTuo Bio with a closing price of 45.34, also up 20.01% [1] Group 2 - The medical device sector saw a net inflow of 1.678 billion yuan from institutional investors, while retail investors experienced a net outflow of 644 million yuan [2] - The top individual stock in terms of net inflow was AiPeng Medical, with a net inflow of 1.57 million yuan, representing 25.59% of its trading volume [3] - Conversely, major outflows were observed in stocks like MaiRui Medical, which had a net outflow of 91.39 million yuan from retail investors, accounting for 2.74% of its trading volume [3]

1月5日，A股市场高开高走迎来2026年开门红，创业板指领涨，沪指重回4000点上方。截至收盘，沪指涨1.38%，录得十二连阳，深成指涨2.24%，创业板 指涨2.85%。全市场成交额高达2.57万亿，较上一个交易日放量5015亿，近4200只个股上涨，其中127只个股涨停。 消息面上，据智通财经报道，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备进行"大规模生产"。 21世纪经济报道记者获悉，去年年初，国家医保局发布对脑机接口康复收费的指导意见，直接推动了脑机接口产业快速发展。目前已有约11个省市出台脑 机接口相关收费标准，且不少公司也透露最新商业化进展。 午后贵金属板块持续走强，兴业银锡封涨停，此前湖南白银涨停，西部黄金、山东黄金等涨幅靠前。消息面上，贵金属市场受突发地缘政治事件催化，现 货白银日内一度涨超5%，站上75美元大关，此外现货黄金日内涨超2%，收复4400美元关口。 板块方面，脑机接口概念全天领涨，三十余只成分股涨停。保险板块爆发，新华保险、中国太保大涨续创历史新高。商业航天概念反复活跃，雷科防务4 连板，中国卫通5天3板。半导体产业链走强，亚翔集 ...

Group 1 - The brain-computer interface (BCI) sector in A-shares experienced a strong surge on January 5, 2026, with stocks like Botao Bio, Sino Medical, and Xiangyu Medical hitting the 20% daily limit up [1] - The medical device ETF rose by 5.6%, while the Hong Kong medical sector also saw gains, with the Hang Seng Pharmaceutical ETF and Hong Kong Stock Connect Medical ETF increasing by 6% and 5.7%, respectively [1] - Elon Musk's Neuralink announced plans for large-scale production of BCI devices in 2026, marking a significant shift from clinical validation to commercial-scale production [1][3] Group 2 - In 2025, China approved 76 innovative drugs for market, surpassing the 48 approved in 2024, with total transaction amounts for innovative drug licensing exceeding $130 billion and over 150 transactions, both setting historical records [1] - The medical device ETF (562600) tracks the CSI Medical Device Index, with the medical device industry comprising 89% and BCI content at 23.14% [3] - The Hang Seng Pharmaceutical ETF (159892) has a scale of 5.564 billion yuan, with top-weighted stocks including BeiGene [3]

Market Overview - The A-share market opened higher on January 5, with the Shanghai Composite Index surpassing 4000 points, closing at 4023.42 points, up 1.38% [2] - The total trading volume in the Shanghai and Shenzhen markets reached 25,462 billion yuan, an increase of 5,011 billion yuan from the previous trading day [2] Sector Performance - The pharmaceutical and biotechnology sectors saw significant gains, with nearly 40 stocks hitting the daily limit or rising over 10%, driven by industry demand recovery and exceeding performance expectations [4] - Non-bank financial stocks, particularly insurance companies, performed well, with several stocks rising over 5% to 7% due to stable growth in investment assets and high dividend strategies [5] - The semiconductor sector also showed strong performance, with multiple stocks rising over 10% [6] Market Sentiment and Predictions - Analysts from Huaxi Securities believe the bull market remains intact, with 2026 expected to be a year of positive factors, including supportive macro policies and improved corporate earnings [8] - Zhongyuan Securities anticipates that the market will stabilize around the 4000-point mark, with a focus on macroeconomic data and overseas liquidity changes [9] - Citic Securities suggests that the balance between external and internal demand will be a significant factor in 2026, with a higher probability of market fluctuations in the early year [10]

Market Performance - The A-share market experienced a "good start" on the first trading day of the new year, with the Shanghai Composite Index rising over 1% and surpassing the 4000-point mark [1] - The technology growth sector led the gains, particularly in the electronics and pharmaceutical biotechnology sectors, with multiple stocks hitting the daily limit [3] - Non-bank financial sectors, especially insurance stocks, also showed strong performance, while sectors like oil and banking experienced adjustments [3] Brain-Computer Interface Sector - The brain-computer interface (BCI) concept sector performed exceptionally well, with stocks like BeiYikang hitting a 30% limit up, and several others, including BoTuo Bio and Sanbo Neuroscience, reaching 20% limit up [3] - Elon Musk announced plans for large-scale production of BCI devices by his company Neuralink, which aims to streamline surgical processes and enhance device control capabilities [3] - Domestic companies are actively engaging in BCI business, with Meihao Medical collaborating with BCI clients, and Xiangyu Medical planning to expand its BCI project to over 700 medical institutions by early 2026 [4] Company Developments - Meihao Medical indicated that artificial cochlear implants are a significant application direction for BCI, although current revenue from this business is still small [4] - Xiangyu Medical aims to establish a comprehensive product matrix for BCI by entering over 1000 top-tier hospitals within the year [4] - Entropy Technology is focusing on developing next-generation BCI algorithms and advancing hybrid biometric recognition and brain signal analysis [4] Hong Kong Market Activity - In the Hong Kong market, BCI-related stocks also showed significant activity, with Nanjing Panda Electronics rising over 40% and other stocks like Micro-Innovation Brain Science experiencing substantial gains [4]

随着马斯克明确给出脑机接口设备的量产时间表，这一前沿赛道正从实验室的科学探索加速走向商业化落地，行业或将迎来从"医疗试验品"向"大 众消费品"跨越的关键转折点。 2026年A股开盘首日，脑机接口板块表现强势。倍益康30CM涨停，三博脑科、翔宇医疗、美好医疗、爱朋医疗、诚益通、伟思医疗等多股20CM 涨停，市场资金对脑机接口商业化前景展现出极高预期。 | 代码 | 名称 | 现价 | 涨跌幅 ▼ | 涨跌 | 换手率 | | --- | --- | --- | --- | --- | --- | | 688108 | 賽诺医疗 | 23.09 | 20.01% | 3.85 | 14.83% | | 300238 | 冠昊生物 | 16.62 | 20.00% | 2.77 | 13.53% | | 300753 | 爰朋医疗 | 33.30 | 20.00% | 5.55 | 21.10% | | 301363 | 美好医疗 | 28.86 | 20.00% | 4.81 | 1.93% | | 688626 | 翔宇医疗 | 72.60 | 20.00% | 12.10 | 3.36% | | 300003 ...